Sickle Cell Disease and Pregnancy

Jain, Dipty; Lodha, Pooja; Colah, Roshan; Atmapoojya, Prachi

doi:10.4084/mjhid.2019.040

Cited by 67 publications

(79 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study the observed incidence of complications was smaller compared to similar studies (Toumba et al, 2008;Kuo and Caughey, 2016;Lao, 2017;Jain et al, 2019;Origa and Comitini, 2019). Thirty two pregnancies (97%) resulted in successful deliveries, only a case of abortion (3%) in a SCD patient, no abortion in thalassemic women, only seven preterm deliveries (21%), of which three were in twin pregnancy, and severe neonatal complications only in 5.7% of children.…”

Section: Delivery and Neonatal Outcomescontrasting

confidence: 68%

“…In this retrospective study, we report the experience of pregnancies in patients with thalassemia major and intermedia and sickle cell disease followed at the Thalassemia Unit of S. Eugenio Hospital of Rome. Moreover we report the maternal and fetal outcomes of the patients comparing with the experiences previously reported in literature (Tuck, 2005;Origa et al, 2010;Leung and Lao, 2012;Voskaridou et al, 2014;Lao, 2017;Carlberg et al, 2018;Jain et al, 2019).…”

Section: Introductionmentioning

confidence: 80%

“…Pregnancies in women with sickle cell disease (SCD) are associated with increased rates of maternal and fetal mortality and adverse outcomes (Eissa et al, 2015;Kuo and Caughey, 2016;Ware et al, 2017;Jain et al, 2019;Patel et al, 2019). The physiological changes of pregnancy (increased metabolic demand, rise of blood viscosity, hypercoagulability) are aggravated in SCD women leading to increased incidence of complications.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pregnancy in Thalassemia and Sickle Cell Disease: The Experience of an Italian Thalassemia Center

Sorrentino

Maffei

Caprari

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

The life expectancy of thalassemia patients has increased significantly in recent years being the most "elderly" patients approaching or are over 50 years old. Consequently, patients' perspectives have changed, leading them to longer-term planning with a consequent increase in their reproductive potential and desire to have children. Crucial points in the management of pregnancy in thalassemia are the iron chelation therapy before and during pregnancy, the antithrombotic prophylaxis, the management of transfusion therapy according to the modified transfusion requirement, a cardiologic monitoring for hemodynamic changes that expose an increased risk of heart failure. Pregnancy in women with sickle cell disease is still associated with increased rates of maternal and fetal mortality and adverse outcomes. Maternal morbidity may be due to acute sickling crises, thromboembolism, infection, and chronic end-organ dysfunction, while neonatal outcomes may be intrauterine growth retardation, preterm delivery, small infants for gestational age, stillbirth, and neonatal death. The management of pregnancy in thalassemia and sickle cell disease requires to be approached by a multidisciplinary team and followed from the pre-conception phase until the post-partum period with a close monitoring of the maternal and fetal conditions, in order to ensure optimal outcome. This approach requires the application of well-defined protocols that cover all the critical aspects of pregnancies in women affected by these pathologies. We describe our experience of spontaneous and non-spontaneous pregnancies in patients with thalassemia major and intermedia and sickle cell disease followed between 1992 and 2018 at the Thalassemia Unit of S. Eugenio Hospital of Rome.

show abstract

Section: Delivery and Neonatal Outcomescontrasting

confidence: 68%

Section: Introductionmentioning

confidence: 80%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy in Thalassemia and Sickle Cell Disease: The Experience of an Italian Thalassemia Center

Sorrentino

Maffei

Caprari

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Indeed, the causes of anemia during pregnancy in developing countries are multifactorial and may be a result of other co-morbidities (worm infestation), complication events (placenta previa, placental abruption, etc. ), chronic diseases (HIV, sickle cell disease, and TB), or nutritional de ciency (inadequate intake of iron and folic acid and/or inadequate iron + folic acid supplementation) [37][38][39][40][41][42][43]. Appropriate community-based strategies to prevent anemia in pregnancy can help to signi cantly reduce the occurrence of maternal anemia and, thereby, avoid progression to fatal outcomes.…”

Section: Discussionmentioning

confidence: 99%

Asymptomatic malaria and anemia among pregnant women during high and low malaria transmission seasons in Burkina Faso: household-based cross-sectional surveys in Burkina Faso, 2013–2017

Rouamba

Samadoulougou

Ouédraogo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Malaria in endemic countries is often asymptomatic during pregnancy, but it has substantial consequences for both the mother and her unborn baby. In Burkina Faso, the prevalence and risk factors of asymptomatic malaria in pregnancy and its main consequence, anemia, during high and low malaria transmission seasons is underexplored at the household level.Methods: Data of 1751 pregnant women from October 2013 to March 2014 and 1931 pregnant women from April 2017 to June 2017 were drawn from two cross-sectional household surveys conducted in 24 health districts of Burkina Faso. Pregnant women were tested for malaria in their household after consenting. Asymptomatic carriage was defined as a positive result from malaria rapid diagnostic tests in the absence of malaria symptoms. Anemia was defined as hemoglobin level less than 11 g/dL.Results: Prevalence of asymptomatic malaria in pregnancy was estimated at 23.9% (95%CI: 20.2–28.0) during the high transmission season (October–November) in 2013. During the low transmission season, it was 12.7% (95%CI: 10.9–14.7) between December and March in 2013–2014 and halved (6.4%; 95%CI: 5.3–7.6) between April and June 2017. Anemia prevalence was estimated at 43.7% (95%CI: 39.3–48.3) during the high transmission season in 2013. During the low transmission season, it was 32.7% (95%CI: 30.1–35.5) between December and March 2013–2014 and 46.6% (95%CI: 44.3–48.9) between April and June, 2017.Conclusion: Prevalence of asymptomatic malaria in pregnancy was significantly higher during the high malaria transmission season while anemia prevalence was lower. Our study provides an opportunity to assess the prevalence of asymptomatic carriage and one of its main consequences, anemia, among pregnant women at the community level throughout the year. In order to mitigate the harmful effects of asymptomatic carriage for both the mother and fetus, health programs aimed at increasing the number of women coming into contact with health workers are necessary.

show abstract

“…There are a limited number of case reports describing the use of HC in pregnancy without harmful effects but the data are insufficient to recommend its general use. [13][14][15] Potential teratogenicity of TKI is clearly a matter of concern, and conclusions regarding the balance of risk and benefit for every TKI are different. As reported by Pye et al congenital abnormalities on imatinib were mostly observed when it was used during organonenesis.…”

Section: Diagnosed During Pregnancymentioning

confidence: 99%

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations

Abruzzese

Mauro

Apperley

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

With survival expectation that of age-matched controls and given excellent response and worldwide access to tyrosine kinase inhibitors (TKI), family planning is increasingly important for a considerable fraction of patients with chronic myeloid leukemia (CML). The potential for therapy discontinuation (“treatment free remission”) can afford the opportunity for a CML patient in deep response to plan and carry a pregnancy to full term without any therapeutic interventions. However, the reality of pregnancy desired or occurring when patients are not eligible for treatment-free remission raises the discussion of therapy choices during pregnancy. To date there are no official guidelines available to assist patients and clinicians with these decisions. This first position paper aims to analyze information published and presented surrounding this challenging area, with focus on different scenarios of disease burden and time from CML diagnosis, including CML discovered during pregnancy and pregnancy during CML treatment. An updated review, supported by data and presented together with authors’ joint recommendations, is aimed to counsel the practical management of CML patients and pregnancy.

show abstract

Sickle Cell Disease and Pregnancy

Cited by 67 publications

References 35 publications

Pregnancy in Thalassemia and Sickle Cell Disease: The Experience of an Italian Thalassemia Center

Pregnancy in Thalassemia and Sickle Cell Disease: The Experience of an Italian Thalassemia Center

Asymptomatic malaria and anemia among pregnant women during high and low malaria transmission seasons in Burkina Faso: household-based cross-sectional surveys in Burkina Faso, 2013–2017

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations

Contact Info

Product

Resources

About